|
 |
Diagnosis and Management of IBS
|
|
Purpose
|
|
Irritable bowel syndrome (IBS) is the most common diagnosis seen by gastroenterologists; IBS accounts for greater than 10% of all primary-care visits. As understanding of the pathophysiology behind IBS has evolved, the diagnosis, work-up and treatment of the syndrome have become more rational and more effective.
|
|
|
Program Overview
|
|
|
This program will discuss current thinking on the pathophysiology, diagnostic criteria and treatment options for IBS. It will discuss the epidemiology of IBS with special reference to the degree to which IBS is underdiagnosed, its economic costs and its effect on patients' quality of life. The evolving role of enteric neurotransmitters in the pathophysiology of IBS will be addressed and various IBS diagnostic criteria will be described. Treatments, both current and upcoming, will be reviewed, with an emphasis on evidence-based clinical practice guidelines.
|
|
|
Audience
|
|
|
This program has been specifically developed to update gastroenterologists and primary care physicians about the most current rationales behind the treatment of IBS.
|
|
|
Learning Objectives
|
Following completion of this CME activity, participants should be better able to:
- Discuss the current data regarding the epidemiology of IBS
- Identify current diagnostic criteria and work-up procedures for IBS
- Discuss current theories regarding the pathophysiology of IBS
- Identify current and future evidence-based treatment options for IBS
|
|
|
Faculty
|
|
|
David A. Katzka, MD
Associate Professor of Medicine
University of Pennsylvania School of Medicine
>> Read Biography
Emeran A. Mayer, MD
Professor of Medicine, Physiology and Psychiatry
UCLA David Geffen School of Medicine
>> Read Biography
Charlene M. Prather, MD
Associate Professor of Internal Medicine
Saint Louis University School of Medicine
>> Read Biography
|
|
|
Faculty Disclosure Information
|
|
|
In accordance with the Accreditation Council for Continuing Medical Education Standards for Commercial Support, faculty members for this activity were each asked to complete financial disclosure forms. Disclosures are provided below.
David A. Katzka, MD
Speakers' Bureau: Lectures: Novartis Pharmaceuticals
Emeran A. Mayer, MD
Consultant: AstraZeneca
Grant/Research Support: GSK, pre-clinical; Novartis Pharmaceuticals, pre-clinical and clinical; Microbia, pre-clinical
Charlene M. Prather, MD
Consultant: Novartis Pharmaceuticals Corporation, Solvay, PAR
Grant/Research Support: AstraZeneca
Speakers' Bureau: Lectures: Novartis Pharmaceuticals
|
|
|
Software Requirements
|
|
|
Internet Explorer (4.0 or greater), Windows 98 and Windows Media Player (7.0 or greater), or Adobe Acrobat (5.0 or greater)
|
|
|
Release Date
|
|
|
May 15, 2004
|
|
|
Expiration Date
|
|
|
May 15, 2006
|
|
|
Fee
|
|
|
Free-of-charge
|
|
|
|
Sponsorship and Support
|
|
|
Sponsored by the AGA. Supported through an unrestricted educational grant from Solvay Pharmaceuticals, Inc.
|
|
|
Program Segments
|
|
|
|
Irritable Bowel Syndrome: Epidemiology
|
|
Epidemiology
Effect on Quality of Life
|
| |
Key Clinical Issues:
What Is the Role of Diminished Quality of Life in Beginning Treatment for IBS? What Is the Role of the Doctor-Patient Relationship in Diagnosing and Treating IBS?
|
|
Irritable Bowel Syndrome: Pathophysiology
|
|
Pathophysiology
Anatomy
Key Role of Serotonin
|
| |
Key Clinical Issues:
Does Serotonin Account for the Triad of IBS Pathophysiology: Altered Gut Motility, Visceral Hypersensitivity and Dysregulation of the Brain-Gut Axis? Irritable Bowel Syndrome: Functional Bowel Disorder or Neurologic Bowel Disease?
|
|
Irritable Bowel Syndrome: Diagnosis
|
|
Diagnostic Criteria
Accuracy of the Diagnostic Criteria
Evidence-based Clinical Practice Guidelines for IBS
|
| |
Key Clinical Issues:
What Is the Role of the Serotonin Agents in a Therapeutic Trial for IBS? Should Physicians Be Concerned Regarding False Negatives in the Diagnostic Work-up of IBS? Does the Prevalence of Organic Disease Differ Between Patients with IBS and the General Population?
|
|
Irritable Bowel Syndrome: Treatment
|
|
Current AGA Recommendations About Treatment of IBS
Current Status of Clinical Trials in IBS
|
| |
Key Clinical Issues:
Evidence-based Management of Irritable Bowel Syndrome: Has It Changed How You Treat IBS? What Is the Best Approach: Global Symptom Relief or Symptomatic Treatment of IBS? What Targets, Other Than Serotonin, Might Play a Vital Role in the Etiology of IBS?
|
|
|
|
|
|
|
|
|
|
